# | Searches | Results |
---|---|---|
1 | Respiratory Syncytial Virus Infections/ | 1279 |
2 | “RSV infection*”.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] | 4504 |
3 | Asthma/ | 211,704 |
4 | “asthma development*”.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] | 1070 |
5 | wheez*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] | 30,231 |
6 | Respiratory Hypersensitivity/ | 3915 |
7 | atopy.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] | 26,375 |
8 | 1 or 2 | 5266 |
9 | 3 or 4 or 5 or 6 or 7 | 244,215 |
10 | 8 and 9 | 976 |
11 | limit 10 to english language | 913 |
12 | limit 11 to “all child (0 to 18 years)” [Limit not valid in Embase; records were retained] | 913 |
13 | limit 12 to journal article [Limit not valid in Embase; records were retained] | 913 |
14 | (later or subsequent*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] | 1,504,151 |
15 | risk factors/ | 537,637 |
16 | “clinical factor*”.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] | 23,741 |
17 | 14 or 15 or 16 | 2,032,400 |
18 | 13 and 17 | 345 |
19 | prophylaxis.mp. | 205,494 |
20 | Primary Prevention/ | 37,244 |
21 | monoclonal antibody.mp. or Antibodies, Monoclonal/ | 261,479 |
22 | palivizumab.mp. or Palivizumab/ | 2796 |
23 | motavizumab.mp. | 252 |
24 | prevention.mp. | 1,698,423 |
25 | 19 or 20 or 24 | 1,786,756 |
26 | 21 or 22 or 23 | 263,326 |
27 | 25 and 26 | 17,965 |
28 | 18 and 27 | 62 |